Medical Device Marketing & Misbranding: Where’s the Line?
Walk into almost any medical conference and you know the scene: a respected physician takes the stage, a bold claim appears on the screen, and phones come out. Photos start circulating on LinkedIn before the session is even over. By dinner, that slide may have traveled farther than any company brochure ever will.
Here’s the question nobody seems eager to ask: What happens when the claim getting the applause is not actually what the product is cleared to do?
Somewhere between competitive positioning, physician advocacy, and the pressure to differentiate, some MedTech companies are getting awfully comfortable near the line. A message that starts as a marketing choice can shape how a physician understands a device and, eventually, how a patient experiences it.
A Slide Is Still a Message
When people hear the word misbranding, they tend to picture something obvious: incorrect packaging, a false label, maybe a misleading advertisement. In MedTech, the message can be much harder to pin down.
Promotion can show up in a sales deck, conference presentation, case video, booth graphic, social post, physician testimonial, or talking point repeated by a representative in the hallway. The format changes, but the responsibility does not.
Under the Federal Food, Drug, and Cosmetic Act, a medical device is misbranded if its labeling is false or misleading. That assessment considers both what the message suggests and whether it leaves out material facts. For restricted devices, false or misleading advertising can also constitute misbranding.
When a company's messaging suggests that a device does something beyond what it is cleared to do, changing the person delivering the message does not resolve the issue. Putting the claim in a physician's PowerPoint does not make it disappear.
The Gray Area Everyone Pretends Is Gray
A product is cleared for one use but discussed as though it does more. A technical phrase suggests a broader indication, while a study title receives more attention than the limitations of the evidence. Before long, "studied" starts sounding suspiciously similar to "cleared."
Add a physician consultant behind the podium, and the message gains credibility without the underlying evidence changing. None of these choices necessarily looks dramatic on its own, which is precisely why they deserve scrutiny.
Inside a marketing meeting, it can all sound like reasonable competitive positioning. The harder question is whether the same language holds up when someone asks to see the clearance.
Physicians Are Paying Attention
There seems to be an assumption in parts of the industry that physicians either will not notice these distinctions or will not care. That’s a dangerous calculation. Physicians understand the difference between preliminary data and published evidence, just as they understand the difference between a clinical use and an FDA-cleared or approved indications.
Once a physician realizes a company has blurred those lines, the problem extends beyond one slide. An exaggerated claim makes the next legitimate claim harder to believe, and a technical stretch gives the audience a reason to scrutinize everything that follows.
A short-term marketing win can become a much longer-term trust problem. That’s a terrible trade.
Trust Is Not the Soft Part of the Strategy
Healthcare companies love to talk about trust, but trust is easy to celebrate when nobody is testing it. The real test comes when a company has to choose between a stronger-sounding claim and a more accurate one.
Deloitte research involving more than 42,500 consumer responses across more than 100 life sciences and healthcare organizations found that trust was the factor most strongly associated with perceived value for MedTech organizations. The same research also pointed to weaknesses around transparency and humanity.
That should get the industry's attention. A brand built around trust should make its claims easier to understand and evaluate. Asking physicians to dig through the instructions for use (IFU) to determine whether a presentation matches the clearance undermines that promise.
When You Use a Physician's Voice, You Are Borrowing Their Trust
Patients trust physicians, and physicians look to colleagues for clinical insight. When a respected physician presents data at a medical conference, the message carries weight. The speaker’s reputation—and the society’s name on the program—give the audience reasons to believe it.
But when that presentation stretches the evidence, where does the liability land? With the physician behind the podium, the company that helped shape the message, or the organization that gave it a platform? Legal liability depends on the circumstances. Who takes responsibility for correcting the record should be a question everyone involved is prepared to answer.
If a company supplied the claims, helped develop the slides, or promoted the presentation afterward, its involvement deserves scrutiny. The physician should be able to defend the evidence they presented. The society should have a process for investigating credible concerns about what was said under its name.
For sessions offered as accredited continuing medical education, ACCME makes the accredited provider responsible for ensuring the content is fair, balanced, and scientifically grounded. That gives the organizer a role that extends beyond filling the room and introducing the speaker.
Once a misleading claim is confirmed, what happens next? Will attendees receive a correction? Will the slides and recording be updated? If the findings cannot be supported, should the presentation or published abstract be withdrawn or retracted? Quietly changing an archived slide does little for the physician who already took the original message back to their practice.
Companies, speakers, and societies all benefit from the credibility of the stage. They should bring the same urgency to addressing a misleading claim that they brought to promoting the presentation. The correction should be as visible as the claim.
And the Damage Does Not Stop With One Company
When one company stretches a claim, it can make physicians more skeptical of the entire category and hospital committees more cautious about new technology. Regulatory and legal teams may add scrutiny, including for companies whose claims actually are supported.
The next company walking into that hospital may have strong clinical evidence and carefully developed messaging. But now part of the conversation is spent answering for a competitor’s promises. Before the team can explain what its technology does, it has to work through doubts someone else created.
That is a frustrating position for companies investing in clinical evidence, regulatory strategy, and long-term data. They have done the work to build something credible, yet they can still face the skepticism left behind by a company that took shortcuts. A bold claim may help one sales conversation while making the next ten harder for everyone else.
This is why credible communication should matter across the industry. Promising technology deserves a fair hearing, and physicians deserve information they can evaluate with confidence. Companies should be asking whether their marketing helps build that confidence—or gives the entire category another trust problem to solve.
Compliance Should Be in the Room Before the Slide Exists
Too many teams still treat regulatory and compliance review as the final stop before a presentation goes out the door. If regulatory sees the deck for the first time the night before a meeting, the problem started long before that email arrived.
Strong MedTech marketing builds defensible messaging from the beginning. Regulatory, clinical, compliance, legal, and marketing teams should understand what is being claimed before the creative team turns it into a headline.
In practice, that means:
Every important claim has support.
Cleared, indicated, studied, and demonstrated are not treated as interchangeable words.
Limitations do not mysteriously disappear from the story.
Financial relationships are disclosed clearly.
Preliminary evidence is presented as preliminary evidence.
Unpublished data is not dressed up like established fact.
Marketing understands the IFU before trying to improve upon it.
This discipline gives teams a message they can use confidently and defend under scrutiny. In MedTech, that is a competitive advantage.
The Person Who Never Saw the Slide
At the end of the conference, the physician leaves the ballroom, the sales team heads to dinner, and the company moves on to the next meeting. The message keeps traveling.
Eventually, it reaches a patient who never saw the presentation, read the clearance, or reviewed the evidence. That patient may have no idea whether the speaker had a financial relationship with the company. They are trusting their physician, who is relying on evidence and on the credibility of the people presenting it.
That chain of trust should shape the marketing decisions made long before anyone takes the stage. Companies should tell compelling factual patient stories, differentiate their technology, and build physician advocates. They should also be confident that their claims will survive after the lights come back on.
The question worth asking in the next marketing meeting is whether the company can defend the claim, including its limitations, when someone looks closely. Then take it one step further:
If the patient were sitting in the room, would we still say it the same way?
That is a useful standard for any company that wants its reputation to last longer than its next presentation.